NASDAQ · CLYM
Healthcare · Biotechnology
$14.11
Down-$0.14 (-0.96%)
Updated Sep 17, 2026, 4:44 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CLYM closed at $14.11 after 20 trading sessions, down 18.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $14.00 | $14.55 | $13.865 | $14.11 | 2.62M |
| Sep 15, 2026 | $14.705 | $14.705 | $13.375 | $13.91 | 1.55M |
| Sep 14, 2026 | $14.49 | $14.96 | $14.30 | $14.56 | 1.09M |
| Sep 11, 2026 | $15.21 | $15.445 | $14.09 | $14.25 | 1.38M |
| Sep 10, 2026 | $14.83 | $15.07 | $14.16 | $14.95 | 1.49M |
| Sep 9, 2026 | $15.82 | $16.1735 | $14.96 | $15.05 | 1.63M |
| Sep 8, 2026 | $15.62 | $16.08 | $15.13 | $15.90 | 918.64K |
| Sep 4, 2026 | $14.49 | $15.96 | $14.28 | $15.52 | 1.5M |
| Sep 3, 2026 | $13.96 | $15.39 | $13.60 | $14.59 | 5.53M |
| Sep 2, 2026 | $14.79 | $15.29 | $14.40 | $15.05 | 2.21M |
| Sep 1, 2026 | $13.88 | $15.03 | $13.09 | $14.82 | 1.97M |
| Aug 31, 2026 | $14.58 | $14.695 | $13.4901 | $13.73 | 1.44M |
| Aug 28, 2026 | $14.86 | $15.13 | $14.37 | $14.57 | 840.93K |
| Aug 27, 2026 | $16.09 | $16.33 | $14.935 | $15.06 | 1.56M |
| Aug 26, 2026 | $17.72 | $17.80 | $16.01 | $16.08 | 1.39M |
| Aug 25, 2026 | $16.75 | $18.33 | $16.75 | $17.84 | 1.2M |
| Aug 24, 2026 | $17.27 | $17.41 | $16.05 | $16.40 | 1.18M |
| Aug 21, 2026 | $17.26 | $17.71 | $17.00 | $17.28 | 957.41K |
| Aug 20, 2026 | $17.16 | $17.45 | $16.72 | $17.02 | 903.93K |
| Aug 19, 2026 | $18.09 | $18.135 | $16.58 | $17.34 | 1.29M |
The latest Smart Investors Daily articles mentioning CLYM.
CLYM research
Company profile and research snapshot.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | Oppenheimer | Outperform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 4, 2026 | B. Riley Securities | Buy | — |
| Sep 3, 2026 | Baird | Outperform | — |
| Sep 3, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Finnhub · May 12, 2026
WELLESLEY HILLS, Mass., May 12, 2026 -- Climb Bio, Inc. , a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of...
Benzinga · May 12, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $15 to $20.
Benzinga · May 8, 2026
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.
Yahoo · May 7, 2026
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; anticipate data from all ongoing trials in 2026 Secured $110 million private placement led by top-tier healthcare investors WELLESLEY HILLS, Mass., May 07, 2026 (GLOBE NEWSWIRE) -
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLYM.
